VTE
- In a retrospective analysis from the US Veterans Administration, in patients weighing >120 kg or with a BMI >40 kg/m2, the use of DOACs, compared with warfarin, was not associated with an increase in bleeding events or recurrent VTE
Perino (Circ Cardiovasc Qual Outcomes 2021) Anticoagulation and outcomes by weight/BMI in VTE
from Veterans Health Administration
from Veterans Health Administration
- In a multicenter retrospective study in an integrated hospital system across 6 US states, in patients with acute VTE weighing >120 kg or with BMI >40 kg/m2, risk of recurrent VTE was lower with apixaban than with warfarin. There was no difference in risk of major bleeding between these groups
Crouch A (Pharmacotherapy 2022)
Multi-center retrospective study evaluating the efficacy
and safety of apixaban versus warfarin for treatment of
venous thromboembolism in patients with severe obesity
Multi-center retrospective study evaluating the efficacy
and safety of apixaban versus warfarin for treatment of
venous thromboembolism in patients with severe obesity
